

In the Claims

Applicant has submitted a new complete claim set indicating marked up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

Please amend the claims as noted below.

1. (Previously presented) An isolated MAGE-A12 HLA class I-binding peptide consisting essentially of the amino acid sequence of SEQ ID NO:6, or a functional variant thereof which binds a HLA-C ~~class-I~~ molecule and which consists essentially of the amino acid sequence of SEQ ID NO:6 with one amino acid addition, substitution or deletion.
2. (Previously presented) An isolated MAGE-A12 HLA-C ~~class-I~~-binding peptide consisting essentially of the amino acid sequence of SEQ ID NO:4, or a functional variant thereof which binds a HLA-C ~~class-I~~ molecule and which consists essentially of the amino acid sequence of SEQ ID NO:4 with one amino acid addition, substitution or deletion.
3. (Previously presented) An isolated MAGE-A12 HLA-C ~~class-I~~-binding peptide consisting essentially of the amino acid sequence of SEQ ID NO:5, or a functional variant thereof which binds a HLA-C ~~class-I~~ molecule and which consists essentially of the amino acid sequence of SEQ ID NO:5 with one amino acid addition, substitution or deletion.
4. (Previously presented) An isolated MAGE-A12 HLA class I binding peptide consisting essentially of a fragment of the amino acid sequence of SEQ ID NO:2 which binds HLA Cw*07, or a functional variant thereof which consists essentially of the fragment of the amino acid sequence of SEQ ID NO:2 with one amino acid addition, substitution or deletion, wherein the functional variant binds HLA Cw*07.
- 5-6. (Canceled)

7. (Original) A composition comprising the isolated MAGE-A12 HLA class I-binding peptide of claim 1 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen.

8. (Original) A composition comprising the isolated MAGE-A12 HLA class I binding peptide of claim 4 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen.

9. (Canceled)

10. (Withdrawn)

11-15. (Canceled)

16. (Withdrawn)

17. (Canceled)

18-20. (Withdrawn)

21-33. (Canceled)

34. (Withdrawn)

35-39. (Canceled)

40-41. (Withdrawn)

42. (Previously presented) A vaccine composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

43. (Original) The vaccine composition of claim 42, further comprising an adjuvant.
44. (Withdrawn)
45. (Canceled)
46. (Withdrawn)
- 47-51. (Canceled)
- 52-53. (Withdrawn)
- 54-57. (Canceled)
58. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 1 wherein the isolated peptide is non-hydrolyzable.
59. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 58 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a $-\psi[\text{CH}_2\text{NH}]$ -reduced amide peptide bond, peptides comprising a $-\psi[\text{COCH}_2]$ -ketomethylene peptide bond, peptides comprising a $-\psi[\text{CH}(\text{CN})\text{NH}]$ -(cyanomethylene)amino peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{CH}(\text{OH})]$ -hydroxyethylene peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{O}]$ -peptide bond, and peptides comprising a $-\psi[\text{CH}_2\text{S}]$ -thiomethylene peptide bond.
60. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 2 wherein the isolated peptide is non-hydrolyzable.

61. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 60 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a $-\psi[\text{CH}_2\text{NH}]$ -reduced amide peptide bond, peptides comprising a $-\psi[\text{COCH}_2]$ -ketomethylene peptide bond, peptides comprising a $-\psi[\text{CH}(\text{CN})\text{NH}]$ -(cyanomethylene)amino peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{CH}(\text{OH})]$ -hydroxyethylene peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{O}]$ -peptide bond, and peptides comprising a $-\psi[\text{CH}_2\text{S}]$ -thiomethylene peptide bond.
62. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 3 wherein the isolated peptide is non-hydrolyzable.
63. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 62 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a $-\psi[\text{CH}_2\text{NH}]$ -reduced amide peptide bond, peptides comprising a $-\psi[\text{COCH}_2]$ -ketomethylene peptide bond, peptides comprising a $-\psi[\text{CH}(\text{CN})\text{NH}]$ -(cyanomethylene)amino peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{CH}(\text{OH})]$ -hydroxyethylene peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{O}]$ -peptide bond, and peptides comprising a $-\psi[\text{CH}_2\text{S}]$ -thiomethylene peptide bond.
64. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 4 wherein the isolated peptide is non-hydrolyzable.
65. (Previously presented) The isolated MAGE-A12 HLA class I-binding peptide of claim 64 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a $-\psi[\text{CH}_2\text{NH}]$ -reduced amide peptide bond, peptides comprising a $-\psi[\text{COCH}_2]$ -ketomethylene peptide bond, peptides comprising a $-\psi[\text{CH}(\text{CN})\text{NH}]$ -(cyanomethylene)amino peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{CH}(\text{OH})]$ -hydroxyethylene peptide bond, peptides comprising a $-\psi[\text{CH}_2\text{O}]$ -peptide bond, and peptides comprising a $-\psi[\text{CH}_2\text{S}]$ -thiomethylene peptide bond.

66. (Previously presented) A composition comprising the isolated MAGE-A12 HLA class I-binding peptide of claim 2 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen.
67. (Previously presented) A composition comprising the isolated MAGE-A12 HLA class I binding peptide of claim 3 and an isolated HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen.
68. (Previously presented) The composition of claim 7, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.
69. (Previously presented) The composition of claim 8, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.
70. (Previously presented) The composition of claim 66, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.
71. (Previously presented) The composition of claim 67, wherein the MAGE-A12 HLA class I-binding peptide and the HLA class I- or class II-binding peptide of a non-MAGE-A12 tumor antigen are combined as a polytope polypeptide.
72. (Previously presented) A vaccine composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier.
73. (Previously presented) A vaccine composition comprising the polypeptide of claim 3 and a pharmaceutically acceptable carrier.

74. (Previously presented) A vaccine composition comprising the polypeptide of claim 4 and a pharmaceutically acceptable carrier.

75. (Previously presented) The vaccine composition of claim 72, further comprising an adjuvant.

76. (Previously presented) The vaccine composition of claim 73, further comprising an adjuvant.

77. (Previously presented) The vaccine composition of claim 74, further comprising an adjuvant.